Glucose tolerance, growth hormone and somatomedin levels in osteosarcoma patients

Print
Published on Tuesday, 26 March 2019

Abstract

Intravenous glucose tolerance, insulin response to glucose, the sensitivity of the periphery to insulin as well as growth hormone and somatomedin levels were determined in osteosarcoma patients and control subjects matched by age, sex, weight an length.

The insulin response to glucose and the peripheral sensitivity to insulin were evaluated by using the individual blood glucose and plasma insulin curves for parameter identification in a mathematical model.

The mean glucose tolerance was significantly decreased in the patients, most likely due to decreased peripheral insulin sensitivity.

Plasma growth hormone levels were normal in all patients which was also the case with somatomedin levels determined by both radioreceptor- and radioimmunoassay.

 

About this publication.

See also:

- Official Web Site: The Di Bella Method;

- Somatostatin in oncology, the overlooked evidences - In vitro, review and in vivo publications;

- The Di Bella Method (A Fixed Part - Somatostatin, Octreotide, Sandostatin LAR, analogues and/or derivatives);

- Congenital fibrosarcoma in complete remission with Somatostatin, Retinoids, Vitamin D3, Vitamin E, Vitamin C, Melatonin, Calcium, Chondroitin sulfate associated with low doses of Cyclophosphamide in a 14-year Follow Up;

- Pancreatic Adenocarcinoma: clinical records on 17 patients treated with Di Bella's Method;

- The Di Bella Method Increases by the 30% the survival rate for Pancreas tumors and for this reason should be proposed as first line therapy for this type of cancer.